Tenaya Therapeutics(US:TNYA)2026-03-11 20:28Clinical Development - The company is focused on advancing clinical-stage gene therapy candidates TN-201 and TN-401, currently in Phase 1b/2 trials to establish safety profiles with anticipated data supporting regulatory alignment by 2026 [516]. - TN-201 demonstrated a 74% decline in cardiac troponin I levels from baseline in all Cohort 1 patients, indicating significant improvement in cardiac health [523]. - The MyClimb study enrolled over 200 pediatric patients with MYBPC3-associated HCM, revealing that 93% had the non-obstructive phenotype, highlighting the urgent need for treatment options [525]. - TN-401 showed a 46% reduction in PVCs for Patient 1 and an 89% reduction for Patient 2, indicating meaningful improvements in electrical stability post-treatment [532]. - The company received an $8.0 million Clinical Grant from CIRM to fund the ongoing Phase 1b/2 RIDGE-1 clinical trial of TN-401 [533]. - TN-201 has received Fast Track, Orphan Drug, and Rare Pediatric Drug Designations from the FDA, along with orphan medicinal product designation from the EC [526]. - The company entered a multi-target research collaboration with Alnylam in March 2026 to identify novel gene targets for cardiovascular disease treatment [517]. - Interim data from MyPEAK-1 indicated that MyBP-C protein levels increased by an average of 4% over time in Cohort 1 patients [522]. - The company plans to present longer-term data from MyPEAK-1 in the first half of 2026 and pursue regulatory alignment for pivotal trial plans for TN-201 [524]. - TN-401 has received Orphan Drug and Fast Track designation from the FDA, emphasizing its potential in treating ARVC [535]. - TN-301, a highly specific HDAC6 inhibitor, shows potential in treating HFpEF and other diseases, with a multi-modal mechanism of action including reductions in inflammation and oxidative stress [536]. - In a Phase 1 clinical trial, TN-301 was well tolerated, with pharmacokinetic results supporting once-daily dosing and showing dose-proportional pharmacodynamic effects [537]. - TN-301 demonstrated significant efficacy in preclinical studies for DMD, showing improved grip strength in mdx mice compared to the FDA-approved pan HDAC inhibitor, givinostat [539]. - The company plans to explore TN-301's development for DMD and other muscular dystrophies, alongside its late-stage development for HFpEF with a strategic pharmaceutical partner [541]. Financial Performance - Research and development expenses decreased by $18.1 million, or 21%, from $86.7 million in 2024 to $68.6 million in 2025, primarily due to workforce reductions and lower clinical trial costs [548][555]. - General and administrative expenses decreased by $4.5 million, or 15%, from $29.2 million in 2024 to $24.7 million in 2025, driven by reductions in employee-related costs [550]. - Net loss for 2025 was $90.6 million, a decrease of $20.5 million, or 18%, compared to a net loss of $111.1 million in 2024 [552]. - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $100.5 million, with an accumulated deficit of $605.0 million [553]. - The company received an $8 million grant from CIRM in February 2025 to support the RIDGE-1 project, contingent on achieving certain clinical milestones [554]. - The company completed a public offering on December 15, 2025, raising net proceeds of $55.8 million from the sale of 50 million units at $1.20 per unit [558]. - The company entered into an "at-the-market" equity offering with a maximum aggregate offering price of up to $75.0 million, with $0.9 million net proceeds from the sale of 822,566 shares in January 2025 [561]. - Operating losses are expected to continue, with anticipated increases in operating expenses as the company advances product candidates and expands clinical trials [562]. - Existing cash, cash equivalents, and investments are projected to meet working capital needs for at least the next twelve months [563]. - Substantial additional funding will be required for product development and commercialization, with potential dilution of stockholder ownership if capital is raised through equity offerings [564]. - Net cash used in operating activities for 2025 was $68.3 million, primarily due to a net loss of $90.6 million and non-cash charges of $24.0 million [567]. - Net cash provided by investing activities for 2025 was $56.1 million, mainly from maturities and sales of marketable securities [570]. - Net cash provided by financing activities for 2025 was $108.4 million, primarily from follow-on offerings [572]. - Future minimum lease payments total approximately $4.8 million for the South San Francisco lease and $8.3 million for the Union City lease [573]. - The company is classified as an emerging growth company and a smaller reporting company, with annual revenue below $100 million and market value of stock held by non-affiliates less than $700 million [586][588]. - Research and development expenses are recorded as incurred, with significant estimates involved in accrued expenses related to ongoing projects [580].